Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

Study Summary

This is a phase 2 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC).